| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Medical Oncology, Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine and the VA Medical Center, Pittsburgh, Pennsylvania [D. R. V., D. S.]; and the Department of Otolaryngology/Head and Neck Surgery, The University of Michigan School of Medicine, Ann Arbor, Michigan [D. R. S., D. E. R., C. J. K., S. R. B., T. E. C.]
Serum antibody reactivity to squamous cell carcinoma of the head and neck (SCCHN) was evaluated in 41 autologous serum-tumor cell line combinations using the protein A hemadsorption assay. Autologous antibody reactivity (median titer of 1:4) was detected in sera from 24 of the patients tested. In 10 cases autologous antibody reactivity could be detected only in undiluted serum precluding further analysis. Analysis of higher titer sera from one patient revealed antibodies that define an antigen expressed on autologous tumor cells cultured from both the primary tumor (UM-SCC-17A) and from a metastasis (UM-SCC-17B). Absorption analysis showed that this antigen was also expressed on 6 of 10 allogeneic SCCHN cell lines but not on autologous fibroblasts or on allogeneic melanoma cell lines. Due to the low titer of autologous antibody reactivity in most sera, we sought to determine if dissociation of immune complexes through acidification and ultrafiltration of serum might enhance detectable antibody reactivity as has been done in previous studies in melanoma. Twelve serum samples from eight patients were subjected to acid dissociation and ultrafiltration (AD-U). Only six of the untreated sera had detectable antibody reactivity against the autologous SCCHN cell line whereas following AD-U all 12 sera had enhanced IgG reactivity against autologous SCCHN. Specificity analysis of one serum sample after dissociation revealed that the antibody detected an antigen common to SCCHN cell lines as well as melanoma, glioma, renal, and colon carcinoma cell lines. Circulating immune complexes may provide a reservoir of antibody with potential diagnostic and therapeutic applications.
1 Supported by USPHS Grant CA 28564.
2 Recipient of a VA Career Development Award.
3 Recipient of USPHS Research Career Development Award CA-00621 from NIH-NCI. To whom requests for reprints should be addressed, at Department of Otolaryngology/Head and Neck Surgery, 6020 KHRI, P. O. Box 0506, 1301 East Ann Street, The University of Michigan, Ann Arbor, MI 48109-0506.
Received 6/ 1/88. Revised 9/19/88. Accepted 12/ 6/88.
This article has been cited by other articles:
![]() |
L. B. E. Shields, C. Gercel-Taylor, C. M. Yashar, T. C. Wan, W. A. Katsanis, J. A. Spinnato, and D. D. Taylor Induction of Immune Responses to Ovarian Tumor Antigens by Multiparity Reproductive Sciences, November 1, 1997; 4(6): 298 - 304. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |